Corteva shares fall 6% on worse-than-expected Q3 results

Corteva Inc. (CTVA) reported Q3 earnings of $0.06 per share, missing estimates of $0.10, and revenue of $1.59B, below the $1.77B forecast. Shares fell 6.4%. Full-year 2026 guidance adjusted, with EPS midpoint at $0.78, above consensus, but EBITDA guidance lowered due to Brazil market conditions. Revenue declined 9% YoY, with Latin America sales down 31% and North America up 7%.

Original reporting
Published Nov 11, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CTVA
Bearish
high confidence
Mentioned
$CTVA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CTVABearishHigh
01

Why it matters

The earnings miss and lowered Brazil outlook drive immediate sell pressure, but full‑year EPS guidance above consensus offers a potential floor.

02

Market read

The report is a primary earnings disclosure with material numbers, prompting a notable price move and sector‑wide implications.

03

What to watch

Strong new‑product performance and 7% North America organic sales growth could mitigate the downside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Corteva is a major U.S. crop‑protection company; its earnings are closely watched by agribusiness investors.

Company-level read

Ticker impact

$CTVABearishHigh confidence
Context

Corteva reported Q3 earnings of $0.06 EPS vs $0.10 estimate and revenue of $1.59B vs $1.77B estimate, causing a 6.4% share decline.

Expected impact

likely further downside as the market prices in the revenue shortfall and softer Brazil outlook

Evidence & confidence

The miss is material and the stock already fell 6% on the news; no mitigating catalyst was provided.

Market effects

Crop protection sector may see broader pressure from Brazil market softness and acetochlor pricing challenges.

Latin America exposure highlighted; Brazil's farmer liquidity constraints could affect peers.

Limited to agriculture inputs; not a broad market driver.

Counterpoint

Guidance beat for full-year EPS may support a short-term bounce if investors focus on the upside.

Key entities

  • Corteva Inc.

    U.S. crop protection firm reporting Q3 results.

Related articles

$CTVAHighAI 8/10

Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook

Corteva, Inc. (CTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook • Third-quarter results reflect strong new product sales growth and continued operational excellence, helping mitigate broader market headwinds • Pricing pressure was concentrated in North America an

$CTVAMed

Mizuho reiterates Corteva stock rating on challenging crop market

Mizuho reiterated an Outperform rating and $16.00 price target for Corteva Inc. (CTVA) after its latest results. The stock is undervalued at $12.14, with a market cap of $8.1 billion. Corteva reported a 17% YoY decline in EBITDA, with regional sales varying. The company reduced its 2026 EBITDA guidance due to challenging market conditions, particularly in Brazil. Q3 results missed expectations, with revenue down 9% YoY.

$CTVAHighAI 8/10

Why is Corteva stock sliding today?

Corteva stock fell 6.4% after reporting Q3 results below expectations, with net sales down 9% YoY and a GAAP loss of $54M. Adjusted EPS dropped 57% to $0.06. The company cited weak Latin America performance and revised 2026 guidance lower, citing Brazil market conditions. Analysts had already cut EPS estimates and price targets. The S&P 500 was flat, indicating the drop was company-specific.

$CTVAHighAI 8/10

Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook

Corteva reported Q3 2026 results with net sales down 9% YoY to $1.59B, organic sales also down 9%. Adjusted EBITDA fell 17% to $222M. Full-year guidance was updated, reflecting weaker Brazil market conditions, with adjusted EBITDA now expected between $1.1B and $1.125B. CEO Luke Kissam cited strong new product performance and operational excellence.